Showing 1,201 - 1,220 results of 1,405 for search '"immunotherapy"', query time: 0.08s Refine Results
  1. 1201

    Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts by Kelley Weinfurtner, David Tischfield, George McClung, Jennifer Crainic, John Gordan, Jing Jiao, Emma E. Furth, Wuyan Li, Erena Tuzneen Supan, Gregory J. Nadolski, Stephen J. Hunt, David E. Kaplan, Terence P.F. Gade

    Published 2025-03-01
    “…Background & Aims: Response to immunotherapy in hepatocellular carcinoma (HCC) is suboptimal with no biomarkers to guide patient selection. …”
    Get full text
    Article
  2. 1202

    Sex-based differences in lung cancer susceptibility and molecular genetics in the 2020s by Berta Mosleh, Pavla Sarova, Sonja Zehetmayer, Felicitas Oberndorfer, Joachim Widder, Helmut Prosch, Marco Idzko, Clemens Aigner, Mir Alireza Hoda, Daniela Gompelmann

    Published 2025-01-01
    “…Objective: The objective of the current study was to reveal timely sex-based differences in patients with lung cancer in the era of immunotherapy and molecularly targeted agents. Methods: We retrospectively analyzed a consecutive cohort of 286 patients (female:male ratio 134:152/47 %:53 %) who were diagnosed with lung cancer between 2020 and 2022 in the pulmonology department of the Medical University of Vienna, Austria. …”
    Get full text
    Article
  3. 1203

    Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma by Yiming Liu, Yusi Wang, Shu Tan, Xiaochen Shi, Jinglin Wen, Dejia Chen, Yue Zhao, Wenjing Pan, Zhaoyang Jia, Chunru Lu, Ge Lou

    Published 2025-02-01
    “…Compared with the subtype C2, the subtype C1 exhibited higher G2MC scores and was associated with faster disease progression, higher clinical staging, poorer pathological types, and lower therapy responsiveness of cisplatin, radiotherapy and immunotherapy. Experiments targeting the feature gene KIF23 revealed its crucial role in reducing HEC-1A sensitivity to cisplatin and radiotherapy. …”
    Get full text
    Article
  4. 1204

    Integrative analysis of anoikis-related prognostic signature to evaluate the immune landscape and predict therapeutic response in stomach adenocarcinoma by Ziyi Zhou, Lanlan Yang, Yuan Fang, Rongzhong Xu, Xi Wang, Yuli Wang, Zhihong Fang

    Published 2025-02-01
    “…The prognostic signature indicated that the low-risk subgroup had better outcomes and significant correlations with tumor microenvironment, immune landscape, immunotherapy response, and drug sensitivity. In addition, single-cell analysis displayed the cell types, the subcellular localization of prognostic genes, and the cellular interaction to reveal the potential molecular communication mechanism of anoikis resistance. …”
    Get full text
    Article
  5. 1205

    Protocol for a first-in-human feasibility study of T regulatory cells (TR004) for inflammatory bowel disease using (ex vivo) Treg expansion (TRIBUTE) by Jennifer Clough, Peter Irving, A Toby Prevost, Graham M Lord, Joana Vasconcelos, James B Canavan, Beverley Rodger, D Macallan

    Published 2025-01-01
    “…This study will explore the preliminary safety and tolerability of a single dose of Treg immunotherapy and will inform the design of a subsequent larger trial.Methods and analysis Four patients will be recruited from gastroenterology clinics at Guy’s and St Thomas’ NHS Foundation Trust. …”
    Get full text
    Article
  6. 1206

    Akkermansia muciniphila Enhances the Antitumor Effect of Cisplatin in Lewis Lung Cancer Mice by Zhuo Chen, Xiang Qian, Shasha Chen, Xiaoxuan Fu, Guanjun Ma, Aiqin Zhang

    Published 2020-01-01
    “…Recently, intestinal flora plays a vital role in the occurrence and development of tumors and there is link between cancer immunotherapy and Akkermansia muciniphila (Akk). However, the therapeutic efficacy of Akk in lung cancer remained unclear. …”
    Get full text
    Article
  7. 1207

    Revolutionizing ESCC prognosis: the efficiency of tumor-infiltrating immune cells (TIIC) signature score by Haixia Wang, Shaowei Ma, Zixin Yang, Ren Niu, Haiyong Zhu, Shujun Li, Shaolin Gao, Zhirong Li, Yanhua Tian

    Published 2025-01-01
    “…Conclusion TIIC signature score was the first time developed which provided a novel strategy and guidance for the prognosis and immunotherapy of ESCC. It also gave the evidence in the important role of immune cells from the TME in the treatment of cancers.…”
    Get full text
    Article
  8. 1208
  9. 1209

    Serum KL-6 levels reflect the severity of interstitial lung disease caused by immune checkpoint inhibitors by Xiaoping Li, Dan Xue, Qiongying Wei, Xuexue Tan

    Published 2025-01-01
    “…Tumor immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a powerful strategy in treating malignant tumors, exhibiting efficacy in both first-line and second-line treatments for advanced non-small cell lung cancer (NSCLC). …”
    Get full text
    Article
  10. 1210

    Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities by Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, Yang Y, Zheng X, Zeng L, Wang J

    Published 2025-01-01
    “…Future approaches to OC treatment must focus on personalized strategies that target the inflammatory TME, integrating anti-inflammatory therapies with immunotherapy to enhance patient outcomes. Continued research into the interplay between inflammation and immune evasion in OC is essential for developing effective, long-lasting treatments.Keywords: ovarian cancer, inflammation-driven mechanisms, evasion of immune response, therapeutic strategies…”
    Get full text
    Article
  11. 1211

    Case report: Clonal evolution analysis of a rare case of meningioma lung metastases identifies actionable alterations in matched longitudinal tumour samples by Nicola Cosgrove, Orla M. Fitzpatrick, Orla M. Fitzpatrick, Liam Grogan, Liam Grogan, Bryan T. Hennessy, Bryan T. Hennessy, Simon J. Furney, Sinead Toomey

    Published 2025-01-01
    “…There was a stepwise increase in tumor mutational burden (TMB) from the primary meningioma to lung metastases, suggesting this patient may have been a candidate for immunotherapy.…”
    Get full text
    Article
  12. 1212

    Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax by Caroline A. Coughlin, Dhanvantri Chahar, Marianna Lekakis, Abdessamad A. Youssfi, Lingxiao Li, Evan Roberts, Natalia Campos Gallego, Claude-Henry Volmar, Ola Landgren, Shaun Brothers, Anthony J. Griswold, Catalina Amador, Daniel Bilbao, Francesco Maura, Jonathan H. Schatz

    Published 2025-02-01
    “…Though potentially curable with frontline combination chemoimmunotherapy, DLBCL carries persistently poor prognosis for those with relapsed or refractory (rel/ref) disease, despite recent advances in immunotherapy. Here, we build on recent findings implicating gain-of-function mutations in the BCL10 signaling protein as drivers of resistance to Bruton’s tyrosine kinase (BTK) inhibitors. …”
    Get full text
    Article
  13. 1213

    Genetic insight into dissecting the immunophenotypes and inflammatory profiles in the pathogenesis of Sjogren syndrome by Jingyi Xu, Shucheng Si, Yijun Han, Lin Zeng, Jinxia Zhao

    Published 2025-01-01
    “…Therefore, our study may provide valuable evidence for future clinical intervention and targeted immunotherapy.…”
    Get full text
    Article
  14. 1214
  15. 1215

    Interferon-gamma rescues dendritic cell calcineurin-dependent responses to Aspergillus fumigatus via Stat3 to Stat1 switching by Amit Adlakha, Thomas J. Williams, Xinxin Shou, Anna K. Reed, Boris Lenhard, Darius Armstrong-James

    Published 2025-02-01
    “…These findings provide key insight into the mechanisms of immunotherapy in organ transplant recipients with invasive fungal diseases.…”
    Get full text
    Article
  16. 1216

    The effect of conditioned media on the cellular proliferation of pancreatic cancer cells, pancreatic stellate cells, and myeloid-derived suppressor cells by Y. Chong, S. Samsudin, D. Bahrani, C. Chang, A. Masamune, S. Ng, N. Ismail, K. Ho

    Published 2025-01-01
    “…Factors from primary tumour cells support cancer cell survival more than those from metastatic cells, indicating potential targets for immunotherapy in early-stage cancers.…”
    Get full text
    Article
  17. 1217

    Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database by Hanzhang Yuan, Jingsheng Cheng, Jun Xia, Zeng Yang, Lixin Xu

    Published 2025-01-01
    “…Conclusion SLC8A2, ATP2B3, and SRCIN1 were identified as underlying biomarkers for glioma associated with prognosis assessments and personal immunotherapy. Graphical Abstract…”
    Get full text
    Article
  18. 1218

    pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG by Jing Wu, Shuang Li, Tete Li, Xinping Lv, Mingyou Zhang, Guoxia Zang, Chong Qi, Yong-Jun Liu, Liang Xu, Jingtao Chen

    Published 2019-01-01
    “…These results are relevant to the further study of the role and mechanism of pDC-induced antitumor effects and may aid in the development of a new strategy for future tumor immunotherapy.…”
    Get full text
    Article
  19. 1219
  20. 1220

    Stemness-related gene signatures as a predictive tool for breast cancer radiosensitivity by Jinzhi Lai, Rongfu Huang, Jingshan Huang

    Published 2025-01-01
    “…Notably, patients in the RS group also exhibited a significantly better response to immunotherapy compared to the RR group. We established a radioresistant BRCA cell line using the MCF-7 breast cancer cell line. …”
    Get full text
    Article